3 assets in Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor

Therapeutic assets addressing Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Ensartinib Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor	National Cancer Institute (NCI)	P2	CCC (53)
Larotrectinib Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor	National Cancer Institute (NCI)	P2	CCC (53)
Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493 Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor	National Cancer Institute (NCI)	P2	CCC (53)